TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00976963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMP/SMX
Description: Take one twice daily for 3 days for urinary tract infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Mix sachet with 1/2 glass cold water and stir. Drink immediately
Study: NCT02257060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocardial Ablation
Study: NCT02920879

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP-level, driving pressure
Description: Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP-level, driving pressure
Description: Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP-level, driving pressure
Description: Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP-level, driving pressure
Description: Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
Study: NCT04137055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-10mg
Description: ZSP0678 tablet administered orally under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-30mg
Description: ZSP0678 tablets administered orally under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-60mg
Description: ZSP0678 tablets administered orally under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-120mg
Description: ZSP0678 tablets administered orally under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-180mg
Description: ZSP0678 tablets administered orally under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-240mg
Description: ZSP0678 tablets administered orally under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-320mg
Description: ZSP0678 tablets administered orally under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678
Description: ZSP0678 tablets administered orally under fasted or fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-Dose 1
Description: ZSP0678 tablets administered orally once daily for 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-Dose 2
Description: ZSP0678 tablets administered orally once daily for 14 Days
Study: NCT02569476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Study: NCT00902915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide plus dexamethasone
Description: peroral application; lenalidomide dosage according to severity grade of renal failure.
Study: NCT02139111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study: NCT03769870

Intervention type: DRUG
Group type: OTHER
Intervention: Teneligliptin 20mg/day + Atorvastatin 40mg/day
Description: cross-over
Study: NCT03612375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study: NCT02139111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study: NCT04003051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use Project Prepare website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02139111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 25 mg
Description: Oral 25 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 45 mg
Description: Oral 45 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 70 mg
Description: Oral 70 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 85 mg
Description: Oral 85 mg capsule - active
Study: NCT01055171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40 mg; Single Administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 mg; Single Dose.
Study: NCT02541682

Intervention type: OTHER
Group type: OTHER
Intervention: TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)
Description: Participants filled out the TEMPS-A survey at their first visit.

Intervention type: OTHER
Group type: OTHER
Intervention: TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)
Description: Participants filled out the TEMPS-A survey at their first visit.

Intervention type: OTHER
Group type: OTHER
Intervention: TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)
Description: Participants filled out the TEMPS-A survey at their first visit.

Intervention type: OTHER
Group type: OTHER
Intervention: TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)
Description: Participants filled out the TEMPS-A survey at their first visit.
Study: NCT04243967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: On the surgery day, the patient is accompanied by music-therapist all the way from her room to the operating theatre in order to monitor and adapt music-therapy intervention.~The patient, prior to the anesthetic, take faces 3 phases of music therapy intervention (1 hour):~* 1° Phase Active Music therapy: the patient takes part in a session of live improvisational music therapy, with the therapist, to elaborate pre-operative stress.~* 2° Phase Relaxation with Receptive Live Music: music therapist play live to relax patients with autogenic training and tunnings breathing.~* 3° Phase playlist listening based on the patient's needs. Patients listen to music with an mp3 player with earphones within the ear canal (H\&H CE mp3/Usb; Headphones on Air in-ear with volume control) with a maximum volume of 60 dB (previously set with a sound level meter).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Standard perioperative management including perioperative care (without the use of music / music therapy)
Study: NCT03478358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE 1
Description: The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TATE
Description: The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE 2
Description: The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE 3
Description: The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)
Description: The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
Description: The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
Study: NCT03711812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Catheter
Description: Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
Study: NCT04137055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-Dose 3
Description: ZSP0678 tablets administered orally once daily for 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.
Study: NCT00038142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: 900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexrazoxane
Description: 900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ImmTher
Description: 900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
Study: NCT03137056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis with Theranova
Description: Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis with FX1000
Description: FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration with FX1000
Description: FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
Study: NCT04112745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static magnet
Description: Static magnet with 2,000 Gauss
Study: NCT03612375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study: NCT01819571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid loading (Voluven)
Description: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
Study: NCT04112745

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Polyvinyl chloride resin material black jewelry
Study: NCT00886691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study: NCT03711812

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Thoracic Epidural Catheter
Description: Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
Study: NCT03722992

Intervention type: OTHER
Group type: OTHER
Intervention: MBSR
Description: Guided yoga and meditation practices
Study: NCT01655641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Includes routine surgical care involved in preventing blood loss during and after surgery.
Study: NCT02762136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiang-sha-liu-jun granules
Description: The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
Study: NCT04685369

Intervention type: OTHER
Intervention: Medical Data extraction
Description: Medical Data extraction
Study: NCT00757081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phosphatidylcholine and deoxycholate
Description: 50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
Study: NCT03605836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 100 mg, BID, oral tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID, oral tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BID, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 200 mg, BID, oral tablets
Study: NCT00964639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: During the surgery infiltration with saline. Thereafter bolus 3 times a day
Study: NCT02095249

Intervention type: DRUG
Group type: OTHER
Intervention: Pimonidazole
Description: Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
Study: NCT02216292

Intervention type: OTHER
Intervention: Control Group
Description: Infants received preterm formula during their first days of life until breastmilk from their own mother was available

Intervention type: OTHER
Intervention: Preterm Single Donor Milk Group
Description: Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
Study: NCT04003051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00634751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days
Study: NCT02272244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support & Navigation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Study: NCT03422757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adaptive Deep Brain Stimulation
Description: The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Deep Brain Stimulation
Description: The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation.
Study: NCT00926562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopromide (Ultravist)
Description: Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol (Visipaque)
Description: Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
Study: NCT03316742

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
Study: NCT03187795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride IR
Description: Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride IR
Description: Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
Study: NCT04458532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: 300 min/wk for 16 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: 150 min/wk for 32 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: 300 min/wk for 32 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: 150 min/wk for 16 weeks
Study: NCT03393897

Intervention type: OTHER
Intervention: Trans oesophageal echocardiography
Description: Transoesophageal echocardiography : it's a standard practice for this patient

Intervention type: OTHER
Intervention: Trendelenburg test
Description: Trendelenburg test : it's a standard practice for this patient